{"entity":{"id":"proxygen","kind":"company","name":"Proxygen","aka":[],"tldr":"Proxygen is a Vienna company that hunts for molecular glues, small molecules that make cells destroy cancer-driving proteins. Its two lead programmes, against p300 and CDK12, are still in the laboratory.","summary":"Proxygen is a Vienna biotechnology company founded from the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences (founders include Georg Winter and Giulio Superti-Furga) that discovers molecular glue degraders and, since April 2026, broader induced proximity therapeutics. Its most advanced programme is a first-in-class oral p300 glue degrader with sub-nanomolar potency and covalent glue pharmacology, aimed at transcription-driven cancers such as prostate, lung and bladder cancer and at CBP-mutant tumours with a synthetic lethal dependence on p300. The second lead, a brain-penetrant CDK12 glue degrader, is directed at aggressive HER2-driven cancers and tumours with central nervous system involvement. Both are preclinical, with development candidate nomination and IND-enabling studies planned over the following 12 to 18 months.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://proxygen.com/"},{"label":"Pipeline and beyond","url":"https://proxygen.com/pipeline-beyond"},{"label":"Platform expansion announcement (April 2026)","url":"https://proxygen.com/chronicle?post=532"}],"tags":[],"related":[],"cancers":["prostate","nsclc","urothelial","breast-her2-positive"],"sections":["targeted-therapy","epigenetics"],"technologies":["protac-degrader","epigenetic-drugs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No financing announcement or pharma collaboration terms (for example the reported Merck deals) could be fetched from the company's news pages, so funding and investors are empty. Founding year not sourced."],"hq":"Vienna","country":"AT","companyType":"biotech","website":"https://proxygen.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/proxygen/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}]}}